T102C

Analytical Considerations for Low Dose DAI Studies

Date
September 10, 2020

Speaker

Speaker Image for Dan Boisvert
Pfizer, Inc.

Related Products

Thumbnail for Analytical Considerations for Low Dose DAI Studies
Analytical Considerations for Low Dose DAI Studies
Dosage Administration Instructions are required prior to clinical dosing throughout a product lifecycle…